stimulation against multiple (unknown) epitopes that are present in vivo. We are currently investigating the putative supportive roles of cotransferred nontumour reactive CD4 T-helper cells in combination with professional antigen presenting cells in mHag specific CTL responses against tumours.
The phosphoinositide 3-kinase (PI3K)/AKT signaling pathway is activated in acute myeloid leukemia (AML) and may control both proliferation and apoptosis of leukemic progenitor cells. 1 The mechanisms leading to PI3K activation are unknown. Class IA PI3K are heterodimeric enzymes composed of a p110 catalytic subunit associated to a regulatory p85 subunit, and signal downstream of tyrosine kinases (TK) and Ras. Three p110 isoforms (a,b,d) have been cloned that display many common structural and functional properties.
2, 3 We recently reported that the p110d isoform is expressed at high level in AML blast cells, whereas expression of a and b isoforms is variable between patients. 4 Moreover, the p110d isoform is the main contributor of PI3K activity in AML blasts, as demonstrated by the complete inhibition of AKT phosphorylation induced by IC87114, a selective p110d inhibitor. 4 Activating mutations in the PI3KCA gene of class IA PI3Ks have been described in solid tumors. 5 These mutations are clustered in exons 9 and 20, coding for the helical and the kinase domains of the p110a protein, with rare mutations in the p85 binding domain and in the C2 domain.
5 These mutants are oncogenic and can promote growth and invasion of human cancer cells, by activating the AKT pathway and the target of rapamycin (TOR) kinase. 6, 7 Given the major role assigned to the p110d isoform in PI3K activity in AML, we wished to determine if it could be genetically altered in AML. We selected 42 patients with primary AML and constitutive activation of PI3K, as assessed by analysis of AKT phosphorylation on Ser473. DNA from 14 normal donors were used as control. All patients expressed the p110d protein at high level and blast cell incubation with a specific p110d inhibitor led to the complete inhibition of AKT phosphorylation, as previously reported. 4 Bone marrow (BM) samples were obtained by sternal aspiration after signed informed consent according to the declaration of Helsinki. The characteristics of these 42 patients are given in Table 1a . All samples contained over 30% blasts (mean: 65%).
We sequenced the 22 exons of the PI3KCD gene coding for the p110d protein. The primers used for PCR amplification were also used as sequencing primers (Table 1b) .
No mutation was found in the DNA of the 42 AML patients studied, except a Y996Y polymorphism (according to SwissProt accession number PIK3CD O0329 protein sequence) as the result of a g.13910C4T mutation in the exon 20 of six patients. The same polymorphism was detected in 1/14 controls.
Our data indicate that the PI3K3CD gene is not mutated in AML. Mutations identical to those reported in PI3KCA, leading to elevated lipid kinase activity, do not explain deregulated PI3K activity in AML. The mechanisms leading to PI3K activation in AML remain unknown. The frequency of PI3K spontaneous activation that we detected in our patients is much higher than the incidence of FLT3 receptor, Ras and c-Kit activating mutations identified in the same patients (Table 1a) . Loss of function of the PTEN phosphatase, activation of the FLT3 receptor by autocrine signaling or overexpression as described in AML, 8, 9 activating mutations of other TK receptors, or of Src kinases may explain PI3K deregulation in AML patients. Nevertheless, independently of the mechanism of p110d activation, specific inhibitors of this PI3K isoform remain of special interest in AML. , P Nguyen The vast majority of patients with acute promyelocytic leukemia (APL, FAB M3) have the t(15;17)(q22;q21) chromosomal translocation (reviewed in Melnick and Licht 1 ). This introduces the gene for PML into the retinoic acid receptor a (RARA) locus, which leads to expression of a PML-RARA fusion. There is convincing evidence that expression of PML-RARA underlies the APL phenotype.
1 Yet, there have been rare cases of APL identified that do not manifest t(15;17). Many of these cases exhibit cryptic rearrangements of PML and RARA.
2 However, in a number of cases a fusion protein different from PML-RARA is expressed. The RARA gene has been consistently involved in these variant translocations. These include the t(11;17)(q23;q21) that expresses a PLZF-RARA fusion; t(5;17)(q35;q21) that encodes NPM-RARA; t(11;17)(q13;q21) that encodes NUMA-RARA; and der(17) with duplication of 17q21.3-q23 that fuses STAT5b to RARA (reviewed in Redner 3 ). These variant rearrangements are rare; fewer than 20 cases of the PLZF-RARA variant have been reported; only four cases of NPM-RARA; and one each of NUMA-RARA and STAT5b-RARA. Nevertheless, these variant translocations hold great importance as 'experiments of nature' and serve as tools to identify common biologic pathways that truly underlie development of the APL phenotype.
We here report a novel case of APL with fusion of RARA with a locus on 3p25. A 72-year-old man presented with a white blood cell count of 20.4 Â 10 9 /l, hemoglobin 10.3 g/l, and platelets 22 Â 10 9 /l. The peripheral blood white cell differential revealed 20% polymorphonuclear leukocytes, 4% bands, 15% lymphocytes, 19% monocytes, 34% blasts, 1% promyelocyte, 6% myelocytes, and 1% metamyelocytes. The majority of blasts demonstrated reniform or bilobed nuclear features. Auer rods were seen in many blasts along with prominent cytoplasmic granulation. The bone marrow biopsy was hypercellular (approximately 80%), with 88% blasts, 1.7% promyelocytes, 0.3% myelocytes, 0.3% polymorphonuclear leukocytes, 0.3% eosinophils, 3% monocytes, 0.3% pronormoblasts, 3.7% normoblasts, and 2.3% lymphocytes. The blasts were similar morphologically to those seen in the peripheral blood. The blasts were positive for chloroacetate esterase staining and were negative for staining with nonspecific esterase. Flow cytometry studies performed on the bone marrow showed the blasts to be positive for CD117, CD13 and/or CD33, partial CD15, CD33, and strongly myeloperoxidase positive. The blasts were negative for expression of CD34 and HLA-DR. The morphologic findings along with the flow cytometry results were consistent with a diagnosis of APL.
Cytogenetic studies indicated a mosaic abnormal chromosome pattern with an apparent normal cell line, represented by six cells, and one, represented by 14 cells, that demonstrated a 47,XY,t(3;17)(p25;q21), þ 8 karyotype (Figure 1 ). Analysis for PML-RARA expression by RT-PCR was indeterminate, owing to poor quality of the extracted RNA. FISH was therefore performed on two hundred unstimulated cells, primarily in interphase. FISH was carried out according to manufacturer instructions, using the Vysis LSI PML/RARA dual color single fusion and LSI RARA dual color break apart DNA probes (Downers Grove, IL). For identification of a partner chromosome, sequential FISH using the Vysis CEP3 DNA probe for the centromeric region of chromosome 3 was performed on the metaphase cells, previously hybridized with the LSI RARA DNA probe.
The PML/RARA probe, when hybridized to a cell containing t(15;17)(q22q21), is expected to result in a pattern of one yellow fusion signal on der(15)t(15;17), a red signal on normal chromosome 15 and a green signal on normal chromosome 17. In the case of an atypical translocation between chromosome 17 and a partner chromosome other than 15, the fusion signal will not be produced. In the current case, this test revealed 98.5% of the cells to be negative for PML-RARA rearrangement (the value of 1.5% positivity is within the Figure 2 FISH: Vysis (Downers Grove, Il) t(15;17) dual color DNA probe was used to determine PML-RARA rearrangement. Separate signals for PML and RARA were seen in both metaphase (a) and interphase spreads (b), indicating absence of PML-RARA fusion. The metaphase spread also indicates that one (green) signal for RARA is located on an A-group sized chromosome, consistent with this being chromosome 3. Metaphase (c) and interphase (d) cells were scored using the LSI RARA dual color DNA probe. 100% showed a split signal, indicating rearrangement of RARA and relocation of the green signal to an A-Group sized chromosome. The metaphase preparation (c) was sequentially hybridized using CEP probes for chromosomes 3 (red) and 17 (green) (e). Comparison of (c) and (e) indicate that the nonsplit RARA hybridzed to chromosome 17, and that the split RARA signal localizes to der (17) and der(3).
